Effect of neutralizing antibodies on NKG2D expression
| Antibody . | NKG2D, media MFI ± SE . | P . | t test versus . |
|---|---|---|---|
| No Ab | 11 ± 2 | ns | Control Ab |
| Control Ab | 8 ± 0 | ||
| MICA/B* | 21 ± 2 | .001 | Control Ab |
| MICB† | 16 ± 2 | .011 | Control Ab |
| MICA | 10 ± 2 | ns | Control Ab |
| ULBP1 + ULBP2 | 9 ± 2 | ns | Control Ab |
| TGF-β1 | 9 ± 3 | ns | Control Ab |
| MICA/B + ULBP1 + ULBP2 | 20 ± 5 | ns | Anti-MICA/B |
| MICB + ULBP1 + ULBP2 | 16 ± 5 | ns | Anti-MICB |
| MICA + MICB | 15 ± 2 | ns | Anti-MICB |
| MICB + TGF-β1 | 18 ± 4 | ns | Anti-MICB |
| No Fc | 7 ± 1 | ns | Control Fc |
| Control Fc | 6 ± 1 | ||
| IL-21R-Fc | 8 ± 2 | ns | Control Fc |
| Antibody . | NKG2D, media MFI ± SE . | P . | t test versus . |
|---|---|---|---|
| No Ab | 11 ± 2 | ns | Control Ab |
| Control Ab | 8 ± 0 | ||
| MICA/B* | 21 ± 2 | .001 | Control Ab |
| MICB† | 16 ± 2 | .011 | Control Ab |
| MICA | 10 ± 2 | ns | Control Ab |
| ULBP1 + ULBP2 | 9 ± 2 | ns | Control Ab |
| TGF-β1 | 9 ± 3 | ns | Control Ab |
| MICA/B + ULBP1 + ULBP2 | 20 ± 5 | ns | Anti-MICA/B |
| MICB + ULBP1 + ULBP2 | 16 ± 5 | ns | Anti-MICB |
| MICA + MICB | 15 ± 2 | ns | Anti-MICB |
| MICB + TGF-β1 | 18 ± 4 | ns | Anti-MICB |
| No Fc | 7 ± 1 | ns | Control Fc |
| Control Fc | 6 ± 1 | ||
| IL-21R-Fc | 8 ± 2 | ns | Control Fc |
Statistical analysis with Student t test. Values are from at least 3 donors tested with different combinations of Abs. They were added to the wells at day 3 after SEB activation, and NKG2D expression was monitored 2 days later on CD8+ T cells that had divided at least once, as measured by loss of CFSE intensity. All Abs were used at 10 μg/mL. Control-Fc and recombinant IL-21R (IL-21R-Fc) were used from 0.1 to 30 μg/mL, and no differences were observed (data shown at 10 μg/mL). Donors tested were n = 3 and were different from those tested with mAbs.
Anti-MICA/B Ab was E16.
Anti-MICB mAb was BMO2.